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Innate drug sensitivity in healthy cells aids identification of lineagespecific anti-cancer therapies and reveals off-target effects. To charac-terize the diversity in drug responses in the major hematopoietic cell
types, we simultaneously assessed their sensitivity to 71 small molecules
utilizing a multi-parametric flow cytometry assay and mapped their pro-
teomic and basal signaling profiles. Unsupervised hierarchical clustering
identified distinct drug responses in healthy cell subsets based on their
cellular lineage. Compared to other cell types, CD19+/B and CD56+/NK
cells were more sensitive to dexamethasone, venetoclax and midostau-
rin, while monocytes were more sensitive to trametinib. Venetoclax
exhibited dose-dependent cell selectivity that inversely correlated to
STAT3 phosphorylation. Lineage specific effect of midostaurin was sim-
ilarly detected in CD19+/B cells from healthy, acute myeloid leukemia
and chronic lymphocytic leukemia samples. Comparison of drug
responses in healthy and neoplastic cells showed that healthy cell
responses are predictive of the corresponding malignant cell response.
Taken together, understanding drug sensitivity in the healthy cell-of-ori-
gin provides opportunities to obtain a new level of therapy precision and
avoid off-target toxicity.
Multi-parametric single cell evaluation defines
distinct drug responses in healthy hematologic
cells that are retained in corresponding 
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ABSTRACT
Introduction
During hematopoiesis, multipotent stem cells and pluripotent precursors undergo
a complex differentiation program to generate a diverse set of blood cell types with
wide-ranging phenotypes and functions.1 This process is initiated and driven by dis-
tinct signaling pathways linked to the different cellular lineages.2 It is likely that
malignant hematopoietic cells exploit many of the signaling pathways essential for
maintaining survival and specific functions of normal cells. Identification and under-
standing of normal hematopoietic cell type specific pathways could, therefore, be
leveraged therapeutically as anti-cancer strategies against their malignant counter-
parts. For example, targeting B-cell antigen receptor (BCR) signaling with ibrutinib
or idelalisib has proven highly effective in treating chronic lymphocytic leukemia
(CLL).3,4 Conversely, modulating molecular targets shared between malignant and
healthy cells may give rise to untoward effects related to
these entities. Although seminal studies have contributed
to the understanding of signaling diversities across blood
cells,5-8 a detailed characterization of cell-type specific vul-
nerabilities within the hematopoietic hierarchy is still
lacking. 
Cell-based phenotypic screens of primary cells have
shown tremendous potential to identify novel therapeu-
tics in leukemia and to explore novel indications for
approved drugs.9,10 However, classical drug screening
methods that assess the sum of all cellular effects in the
bone marrow (BM) or blood restrict the ability to evaluate
drug responses in populations affected by rare diseases
and is influenced by the more abundant cell types in the
sample. Flow cytometry presents a functional platform for
dissecting the complexity of hematopoiesis, allowing
characterization of the different cell populations.
Applying flow cytometry in functional screens allows for
a higher throughput (HTS) assessment of vulnerabilities to
a large set of oncology drugs in leukemic cells with
improved precision, and to compartmentalize drug
responses between malignant and healthy cell subsets.
However, preclinical flow cytometric-based high through-
put functional screens are still limited by numerous wash-
ing steps and small cell population numbers, which can
compromise the robustness of the assay.
In this study, we developed a high throughput no-wash
flow cytometry assay that enabled us to monitor dose
responses of 71 oncology compounds simultaneously on
multiple hematopoietic cell populations defined by their
surface antigen expression. To map the drug responses to
the proteome and basal signaling profiles of the different
cell types, we utilized mass spectrometry (MS) and mass
cytometry (CyTOF) in both healthy and malignant hema-
tologic samples. Finally, we compared inhibition profiles
for those small molecules in a cohort of 281 primary sam-
ples representing a diverse set of hematologic malignancies
to assess whether healthy cell-specific responses can be
exploited in a leukemic context. A graphical overview of
the study and cohorts is provided in Figure 1. Our results
strongly suggest that drug responses are highly specific to
cell lineages and often linked to intrinsic cell signaling pres-
ent in those cell types. We provide evidence that cell-spe-
cific responses could potentially be applied to identify new
clinical applications of therapies and discover relevant non-
oncogenic-dependent activities of small molecules.
Methods
Patient specimens and cohorts
Bone marrow and peripheral blood (PB) samples from 332
donors were collected after written informed consent (Studies:
239/13/03/00/2010, 303/13/03/01/2011, REK2016/253 and
REK2012/2247) following protocols approved by local institution-
al review boards (Helsinki University Hospital Comprehensive
Cancer Center and Haukeland University Hospital) in compliance
with the Declaration of Helsinki. Samples were allocated to four
patient cohorts (I-IV). Cohort I included three healthy PB samples
used for flow cytometry screening with 71 drugs, plus three acute
myeloid leukemia (AML) and ten multiple myeloma (MM) sam-
ples which were tested with bortezomib, clofarabine, dexametha-
sone, omipalisib, venetoclax and navitoclax. Cohort II included 17
samples from two healthy, eight AML with (n=5) or without
FLT3-ITD mutations (n=3), and seven CLL patients tested against
midostaurin, trametinib and dasatinib. Cohort III (n=281) included
231 BM aspirates from a diverse collection of leukemia and 50
MM patients (CD138+ enriched). Four healthy BM aspirates sub-
jected to magnetic bead-based enrichment using EasySep™ human
CD138, CD3, CD19, CD14 and CD34 positive selection kits
(StemCell Technologies), served as healthy cell-of-origin samples
for comparison against the malignant cell counterparts. CyTOF
was performed on 14 samples in Cohort IV. PB from healthy
donors (n=3), AML (n=6), B-cell acute lymphoblastic leukemia (B-
ALL) (n=2), and matched BM samples from the same healthy
donors were included. An overview of the cohorts and experimen-
tal design is provided in Figure 1.
Proteome analysis
10 mg of whole cell protein lysates, prepared from purified CD3,
CD19 and CD14 fractions from healthy (n=2) and MM (n=4) sam-
ples, were digested and loaded (500 ng) on to a Q-Exactive mass
spectrometer connected to a Dionex Ultimate 3000 (RSLCnano)
chromatography system (Thermo Scientific). Protein identifica-
tion and label-free quantification (LFQ) normalization of tandem
mass spectrometry (MS/MS) data were performed using
MaxQuant v1.5.2.8. 
Mass cytometry
For mass cytometry (CyTOF), the 14 samples described in
cohort IV were fixed, barcoded (Fluidigm), pooled into a single
sample and stained with the antibody panels (Online
Supplementary Table S1). Acquisition of samples was performed
using a Helios mass cytometer (Fluidigm). Data were analyzed
using FlowJo v.10.2 and Cytobank (Cytobank Inc.).  
High throughput flow cytometry and cell viability assay
High throughput flow cytometry (HTFC) assays were per-
formed in both 384-well (n=3, 71 drugs, 5 concentrations) and 96-
well plate formats (n=33) using IntelliCyt iQue Screener PLUS. A
detailed optimization protocol is provided in the Online
Supplementary Methods. A list of the antibodies is provided in
Online Supplementary Table S1. Data were analyzed using ForeCyt
software (Intellicyt). The gating strategy, cell composition and list
of compounds are provided in Online Supplementary Figures S1-S3.
CellTiter-Glo® luminescent viability assay was used based on a
previously described method.9,16
Statistical analysis of drug sensitivity data
Cell counts (HTFC) or luminescence intensity were used as
input for Dotmatics (Dotmatics Ltd.) or Graphpad Prism 8.0 to
generate dose response graphs, which were subsequently applied
to calculate drug sensitivity score (DSS) as described by Yadav et
al.16 Comparisons between groups were tested with ANOVA and
with Tukey’s multiple comparison test to derive significance. A
two-tailed P<0.05 was considered significant. 
Results 
Distinct drug response profiles in hematologic cell
subsets are tied to cell lineages
To simultaneously monitor drug effects on a large col-
lection (n=71) of samples in multiple cell types, we applied
a multiplexed, no-wash flow cytometry-based assay
(detailed in the Online Supplementary Methods). We first
tested ex vivo response to the 71 compounds (Online
Supplementary Table S2 and  Online Supplementary Figure
S3) in B (CD19+), natural killer (NK, CD56+), T-helper cells
(THC, CD3+CD4+), cytotoxic T lymphocytes (CTL,
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CD3+CD8+), NK-T cells (NK-T, CD3+CD56+), and mono-
cytes (CD14+) using three healthy blood samples to gener-
ate a global view of response profiles. Unsupervised hier-
archical clustering of DSS of the screened samples segre-
gated in three major clusters based on cellular lineages
(Figure 2A). Monocytes formed a single cluster and dis-
played selective sensitivity to MEK/ERK inhibitors and the
kinase inhibitor dasatinib (Figure 2A). The MEK inhibitor
trametinib was similarly active in BM derived CD14+ cells
from healthy and AML samples (Online Supplementary
Figure S4A). However, reduced efficacy of dasatinib in BM
monocytes was noted compared to those derived from
blood (Online Supplementary Figure S4B). B and NK cells
showed similar drug response profiles with higher sensi-
tivity to the glucocorticoid dexamethasone, BCL2
inhibitor venetoclax and pan-kinase inhibitor midostaurin
Innate drug responses in hematologic cell populations
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Figure 1. Overview of the study.
Schematic diagram summarizing
the study design, datasets and
analytical framework of the study.
Bone marrow (BM) and peripheral
blood (PB) samples from both
healthy individuals and cancer
patients were subjected to drug
sensitivity assessment. Single cell
drug sensitivity assay using the
iQue® Screener PLUS flow
cytometer was performed in 96-
and 384-well plates to monitor
drug effects on ten and six
hematopoietic cell subtypes,
respectively. Immunophenotypic
details and cellular proportions of
the analyzed cell types are provid-
ed in Online Supplementary
Figure S1A-D, Figure S2 and
Online Supplementary Table S3,
respectively. 71 drugs in 384-well
plates and six drugs in 96-well
plates were tested. Proteomic
analysis was performed on three
cell subsets (monocytes, T and B
cells) from two healthy individuals
and four myeloma patients. Basal
phosphorylation of nine signaling
proteins involved in MAPK, JAK-
STAT, PI3K-AKT-mTOR and NF-κB
signaling was monitored in 14
samples. Healthy BM samples
from four healthy individuals were
subjected to CD34, CD3, CD14,
CD19 and CD138 cell enrichment
and tested against 71 small mole-
cules with cell viability as the end
point readout using the CellTiter-
Glo® assay. A comparison of ex
vivo drug response in healthy and
corresponding malignant cell
types was performed for six drugs
in 281 primary patient samples
representing different hematolog-
ic malignancies. Samples included
both published and unpublished
datasets from chronic myeloid
leukemia (CML, n=13),11,12, chronic
myelomonocytic leukemia (CMML,
n=11),12 myelodysplastic syn-
dromes (MDS, n=4), acute myeloid
leukemia (AML, n=145),9,12 B-cell
acute lymphoblastic leukemia (B-
ALL, n=14),13 chronic lymphocytic
leukemia (CLL, n=4),12 T-cell pro-
lymphocytic leukemia (T-PLL,
n=40),14 multiple myeloma (MM,
n=50),15 and other hematologic
malignancies (n=6). PLL: prolym-
phocytic leukemia. 
compared to other cell types. Except for NK-T cells from
one donor, all T-cell subsets formed a distinct cluster. 
Based on observations from the primary screen, we
focused our in-depth analysis on six compounds display-
ing either non-selective (proteasome inhibitor bortezomib
and nucleoside analog clofarabine) or cell-selective (dex-
amethasone, venetoclax, pan-BCL2 inhibitor navitoclax
and PI3K/mTOR inhibitor omipalisib) responses. Sixteen
samples (Cohort I) derived from 10 MM, 3 AML and 3
healthy donors were tested utilizing two antibody panels
M.M. Majumder et al.
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Figure 2. Distinct drug respons-
es observed in immune sub-
sets are tied to cell lineages.
(A) A drug sensitivity score
(DSS),16 which is a modified
form of the area under the
curve (AUC) calculation, was
used to quantitate drug
responses among the different
detected cell populations.
Higher DSS values (DSS>10)
indicate higher sensitivity to the
individual drug. The heatmap
displays a summary view of
hierarchical clustering analysis
with DSS scores for six cell sub-
sets in three peripheral blood
(PB) samples from healthy con-
trols (marked as HC-1, 2 and 3).
Immunophenotyping of
hematopoietic cell types was
performed on the basis of their
known surface antigen expres-
sion profiles (see also Online
Supplementary Figure S1A).
Monocytes and T-cell subsets
formed two separate clusters. B
and natural killer (NK) cells had
similar drug response patterns.
Small molecules that were test-
ed along with their functional
classes are displayed in Online
Supplementary Figure S3. DSS
scores and IC50 values for all
71 drugs are provided in Online
Supplementary Table S2. (B)
Differential effect of borte-
zomib, dexamethasone, clo-
farabine, venetoclax, navitoclax
and omipalisib on hematopoiet-
ic cell subsets presented as
mean values from 16 samples
derived from three healthy,
three acute myeloid leukemia
(AML) and ten multiple myelo-
ma (MM) patients (Cohort I).
Highest variation was observed
for BCL2 inhibitors (venetoclax
and navitoclax) and dexametha-
sone between myeloid and lym-
phoid lineages. Monocytes
were resistant to both of these
drug classes. A concentration-
dependent increase in num-
bers of CD3+ cells was observed
for omipalisib at 10 and 100
nM. The proportion of cells
detected in these analyzed
samples are presented in
Online Supplementary Table
S3. 
A
B
(Online Supplementary Table S1) in 96-well plates to pro-
vide a direct comparison between cell types derived from
healthy donors and those derived from patients with iden-
tical immunophenotypes. Moreover, this enabled detec-
tion of drug responses in rare cell subsets, such as plasma
cells (CD138+) and progenitor cells (CD34+CD38- or
CD34+CD38+). 
While ex vivo response to the proteasome inhibitor
bortezomib was detected in most cell types (Figure 2B),
CD138+CD38- plasma cells were resistant compared to
CD138+CD38+ or other cells (Online Supplementary Figure
S5). A higher response to the nucleoside analog clofara-
bine was noted for CD3+CD4- and CD34+CD38+ cells
compared to CD3+CD4+ or CD34+CD38- cells.
Dexamethasone depleted CD19+ and CD56+ cells and
induced a dose-dependent increase in the CD14+ cell
count (Figure 2B).  T-cell subsets were insensitive to
PI3K/mTOR inhibitor omipalisib. A similar effect for sev-
eral molecules targeting the PI3K-mTOR signaling axis
was observed in CD3+ enriched cells tested with a cell via-
bility assay (Online Supplementary Figure S6). Surprisingly,
an increase in CD3+ cell count was noted at concentrations
of 10 and 100 nM (Figure 2B).  Apart from individual vari-
ations, distinct drug efficacies associated with healthy cell
lineages were detected equally in all patient specimens
(Figure 2B and Online Supplementary Figure S7). 
Venetoclax shows variable dose-dependent efficacy on
hematopoietic cell types 
Preclinical and clinical activity of venetoclax has been
well documented for several B-cell malignancies.17-20 We
measured the response to venetoclax, which is highly
selective for BCL2, and navitoclax, which targets BCL2,
BCL-W and BCL-XL. Both inhibitors were similarly effec-
tive against lymphocytes (Figure 2B). Within the lympho-
cyte compartment, the highest sensitivity to venetoclax
was detected for CD19+ cells (Figures 2B, and 3A and B)
with the majority of samples (Cohort I) responding at sub-
nanomolar concentrations (IC50, 0.4-12 nM). Activity
towards CD3+CD4- cells was observed at 10-100-fold
higher concentrations (IC50, 8-140 nM). A further reduc-
tion in response (Figure 3B) was observed for CD56+,
CD3+CD4+ and CD3+CD56+ cells (IC50, ≅100 nM to 1
mM). Monocytes and granulocytes were sensitive to BCL2
inhibitors only at the highest concentration (10 mM) and
were considered largely resistant (Figure 2B). This dose-
dependent effect on cell types is particularly relevant
when treating elderly patients, with frequent age-related
Innate drug responses in hematologic cell populations
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Figure 3. Variable dose-dependent activity of venetoclax on leukocytes. (A) Scatter diagram displaying dose-dependent cytotoxicity of venetoclax (1-10,000 nM) in
CD45+ (upper panel) and CD45+CD19+ (lower panel) cells for a single patient.  (B)  Averaged dose response graphs generated for different immune cell subtypes
derived from healthy (n=3), acute myeloid leukemia (AML) (n=3), and multiple myeloma (MM) (n=10) samples showed venetoclax sensitivity in CD19+/B cells with
an IC50 <1 nM. CD3+CD4- cytotoxic T cells were more sensitive compared to CD3+CD4+ T-helper cells. Data are presented as  mean±standard error of mean responses
for the tested samples in each disease group. Mean IC50 values for the analyzed samples are listed in Online Supplementary Table S4.
A
B
decline in drug metabolism and excretion,21,22 which can
result in drug accumulation leading to unintended effects
on other immune cells. Venetoclax displayed similar cell-
specific effects in all tested samples, whether healthy or
malignant, suggesting the variation in response is purely
lineage specific.
Lineage specific effect of midostaurin on CD19+
cells is comparable to FLT3-mutated acute myeloid
leukemia cells
In our primary screen, we observed selective depletion
of B and NK cells in PB samples (n=3) treated with
midostaurin (Figure 2A and Online Supplementary Figure
S8A), which is approved for treating FLT3-mutated AML
and systemic mastocytosis.23,24 To evaluate CD19+ cell
specificity in malignant cells such as in CLL and to com-
pare the response to FLT3-ITD-mutated AML cells, we
tested midostaurin in 17 additional samples (Cohort II)
derived from healthy (n=2), CLL (n=7), and AML patients
with wild-type (WT) FLT3 (n=3) or harboring the FLT3-
ITD mutation (n=5). Variable sensitivity was noted in the
CD34+CD38- population, presumably leukemic stem cells,
from all tested AML samples regardless of FLT3 mutation
status (Figure 4A). CD34+CD38+/blast cells from all FLT3-
ITD mutated AML samples were sensitive (median IC50,
554 nM) (Figure 4B). Remarkable sensitivity (IC50, 16 nM)
was detected in the CD34+CD38+ fraction from one of the
three WT samples (Online Supplementary Figure S8B).
While CD34+CD38- cells from healthy donors were insen-
sitive, CD34+CD38+ cells from one healthy individual
responded similarly to FLT3-ITD-mutated AML samples
(Online Supplementary Figure S8B). Importantly, we
observed high efficacy against CD19+ cells in all tested
samples including those derived from CLL patients (Figure
4C, D and Online Supplementary Figure S8C) indicating a
lineage specific effect. The effect on CD19+/B cells (medi-
an IC50, 314 nM) was comparable to FLT3-ITD mutated
AML CD34+CD38+ (blast) cells (Figure 4B and C). Our
results suggest a need for further investigation to evaluate
midostaurin efficacy in diseases affecting B-cell lineages
such as CLL.
Characterizing protein abundance and basal cell 
signaling contributing to innate cellular response 
to therapies
Having determined lineage specificity of the tested
small molecules, we next explored whether protein abun-
dance or basal signaling profiles of specific cell popula-
tions could explain the innate cellular responses. We also
investigated whether healthy cells share identical basal
activity for signaling proteins as patient-derived cells or
whether basal intracellular signaling was deregulated dur-
ing malignant transformation. To characterize and com-
pare the proteomic background of healthy hematopoietic
M.M. Majumder et al.
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Figure 4. Effect of midostaurin on the viability of CD34+CD38-, CD34+CD38+ and CD19+ cells derived from healthy donors, and acute myeloid leukemia (AML) or
chronic lymphocytic leukemia (CLL) patients. Averaged dose response curves for disease categories are presented as mean±standard error of mean. (A) While
midostaurin treatment had no effect on CD34+CD38- cells from healthy individuals, variable sensitivity was detected in AML samples.  (B)  CD34+CD38+ cells derived
from FLT3-ITD-mutated AML samples displayed similar sensitivity (median IC50, 554nM). (C)  CD19+ cells derived from healthy donor or patient samples showed com-
parable sensitivity at a median IC50 of 319 nM. Individual dose response curves are provided in Online Supplementary Figure S8C. (D) Scatter plot showing dose
responses for midostaurin in CD19+ cells from a CLL patient. The percentage of CD19+ live cells present in midostaurin-treated wells compared to untreated cells is
displayed numerically on the plot. Cellular proportions for these samples are provided in Online Supplementary Table S5. Related IC50 values are provided in Online
Supplementary Table S6. 
A B C
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Figure 5. Differences in protein expression between
hematopoietic cell subsets. (A) Venn diagram represen-
tation of unique and commonly detected proteins using
mass spectrometry across healthy T cells, B cells and
monocytes. Uniquely detected proteins corresponded to
their cellular functions shown in the inset boxes. Out of
1,060 proteins detected in lysates from two healthy and
four multiple myeloma (MM) samples, abundance of
753 commonly detected proteins was compared
between the three cell types. A complete list of proteins
and their corresponding abundance values are provided
in Online Supplementary Table S7. (B)  Significantly
higher expression of S100A8/A9, CAT, IDH1, CES1 and
GPX1 was detected in healthy monocytes.  (C and D)
Heatmap summarizing the expression of proteins that
significantly discriminated three cell types in healthy
control (HC) and MM samples, respectively (false dis-
covery rate <0.05). The data presented here are nor-
malized label-free quantification (LFQ) intensity values
for the proteins. 
A
B
C
D
cells, we utilized a mass spectrometry-based quantitative
proteomics approach to profile B cells (CD19+), T cells
(CD3+) and monocytes (CD14+) derived from two healthy
donors (Figure 5). We then employed CyTOF to compare
the basal activity of nine proteins (in healthy and leukemic
cell subsets) involved in MAPK, JAK-STAT, NF-κB and
PI3K-mTOR signaling, which are commonly activated in
many hematologic malignancies25-28 (Figure 6). By sample
barcoding and subsequent pooling prior to antibody stain-
ing, CyTOF allows for direct comparison of the phospho-
rylation level of target proteins between multiple donors
with high fidelity.19,20
Monocytes show higher expression of calprotectin
(S100A8/S100A9), which is associated with dexamethasone
resistance - By quantitative mass spectrometry-based pro-
teomics, a total of 1,060 proteins were detected. Among
these, 163, 131 and 13 proteins were only identified in
CD3, CD14 and CD19 lysates, respectively (Figure 5A,
Online Supplementary Table S7). The uniquely expressed
proteins were associated with biological processes consis-
tent with the functional differences between these cell
types (Online Supplementary Figure S9). For instance, the
proteome signature in monocytes was enriched in biolog-
ical processes related to phagosome maturation
(ATP6V0D1, CTSS, M6PR), autophagy (ATG3, LAMP2),
PPAR-α/RARα activation (IL1β, p38 MAPK, GPD2,
PLCG2), and STAT3 signaling (IGF2R, RAC1, p38 MAPK).
Immunoglobulins (IGLL1, IGHA1) were identified in B-
cell fractions.  T cells expressed proteins related to T-cell
receptor signaling (CD8A, CD247, LCK, ZAP70),
granzyme signaling (GZMA, PRF1), and oxidative phos-
phorylation (ATP5I, NDUFA8, NDUFB3, UQCRB).
Besides observed differences in the abundance of proteins,
variable expression in commonly detected proteins was
noted (Figure 5B and C). Enzymes associated with scav-
enging reactive oxygen species such as catalase (CAT) and
glutathione peroxidase 1 (GPX1) were expressed at a sig-
nificantly higher (P<0.001) level in monocytes (Figure 5B).
In addition, monocytes exhibited elevated expression of
isocitrate dehydrogenase 1 (IDH1), carboxylesterase 1
(CES1), and inflammatory protein calprotectin, a het-
erodimer of two proteins S100A8/S100A9 that can medi-
ate dexamethasone resistance in patients.29,30 We further
compared the protein expression profiles for these cell
subsets between healthy and four MM patients, and
found an identical pattern of expression for CAT, GPX1
and S100A8/9 proteins (Figure 5D). While expression of 16
proteins differed between healthy and MM samples [false
discovery rate (FDR) < 0.05], no significant differences
were noted for CD14+ and CD3+ lysates (< 3 proteins). 
Mapping shared signaling activities in healthy and leukemic
hematopoietic cell subsets - NF-κB phosphorylation was
detected in most cell types. Compared to other cell types,
higher pNF-κB was detected in T/CD3 cells (Online
Supplementary Figure S10). Significantly higher mTOR sig-
naling, as measured by p4E-BP1 and pPLC-g1, was
observed in healthy CD34+CD38+ cells, monocytes, gran-
ulocytes (neutrophils) and B cells (Figure 6A-C). These cell
types also tended to have elevated sensitivity to omipalis-
ib (PI3K/mTOR inhibitor) compared to other cell types in
healthy or malignant samples (Figure 2B and Figure 7E). T
cells lacking sensitivity to PI3K/mTOR inhibitors showed
reduced mTOR signaling activity (Figure 6A-C).
CD34+CD38+ cells also exhibited high levels of ERK phos-
phorylation (Figure 6A-C). ERK phosphorylation status,
however, did not correlate to increased trametinib sensi-
tivity in monocytes.  An inverse relation between pSTAT3
levels and venetoclax sensitivity was observed among the
different cell populations. Heightened levels of pSTAT3
were detected in monocytes and granulocytes, which
lacked sensitivity to venetoclax (Figure 6A-D). In contrast,
a lower level of pSTAT3 was observed in venetoclax sen-
sitive B and NK cells. Two related but distinct cell types,
CD3+CD4+ and CD3+CD8+ T cells, exhibited a difference
in the level of pSTAT3 (Figure 6B) that might explain their
subtle difference in sensitivity to venetoclax (Figure 6D).
Comparison of signaling patterns detected in healthy PB
or BM cells to corresponding leukemic cells expressing
identical surface markers revealed remarkable similarity
(Figure 6A-C), strengthening their association with cellular
phenotypes. Furthermore, monitoring changes in signaling
pattern for these proteins upon treatment with increasing
concentrations (0 nM, 10 nM and 10 mM) of venetoclax in
healthy PB (n=3), revealed that the directionality or mag-
nitude of signaling changes for some of these proteins (i.e.
pPLC-g1 and pCREB) were also similar across these cell
types (Online Supplementary Figure S11). 
Innate drug sensitivities in cell subsets are retained 
in their malignant counterparts in different 
hematologic malignancies
To further confirm the similarity in drug responses
between healthy and patient-derived cell subsets
observed using the single cell assay, we compared ex vivo
drug responses detected in bead-enriched healthy cells
(CD3+, CD14+, CD19+, CD34+ and CD138+) to a cohort of
281 primary samples derived from multiple hematologic
malignancies. For these analyses, we generated data
using the CellTiter-Glo® viability assay. In agreement
with non-selective effects detected on healthy cell types,
bortezomib activity was detected in a wide range of
hematologic malignancies (Figure 7A). The highest clo-
farabine efficacy was observed in CD3+ T cells and in the
T-cell prolymphocytic leukemia (T-PLL) patient subset
(Figure 7B), which is reflective of the clinical success
observed with other purine analogs (fludarabine or
cladribine) in T-PLL. Reduced activity of the purine ana-
log clofarabine was detected in both healthy and myelo-
ma derived CD138+ cells. Although dexamethasone was
found to be most effective in B-ALL and CLL, modest ex
vivo effects were observed in other lymphocytic and plas-
ma cell malignancies, including T-ALL, T-PLL, B-PLL, and
MM (Figure 7C). Disease-specific acquisition of sensitiv-
ity was also noted in a subset of AML patients, which
was undetectable in healthy CD34+ (Figure 7C) or
CD34+CD38+ (Figure 4B) cells. T-cell malignancies, simi-
lar to healthy T cells, showed no response to omipalisib.
Consistent with responses observed in healthy B cells, a
higher response to venetoclax was detected in malignant
B-cell types (Figure 7F). T-PLL samples also exhibited
sensitivity to venetoclax, which has been tested more
recently in two T-PLL patients with measurable clinical
benefit.32 Venetoclax response agreed with navitoclax
responses in B-cell diseases (Figure 7F). Increased sensi-
tivity to navitoclax compared to venetoclax was detected
in CML, T-ALL, and MM samples (Figure 7E and F). B-
cell specific responses to midostaurin were detected in
CLL and ALL samples (Figure 4C and Online
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Supplementary Figure S12). Collectively, the comparison
of lineage specific drug responses between healthy indi-
viduals and those derived from malignancies where the
cell-of-origin is affected shows remarkable similarity.
These results also highlight the fact that innate drug
responses are often retained during cellular transforma-
tion, which could guide identification of lineage specific
anticancer therapies for leukemia.
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Figure 6. Mass cytometry (CyTOF) profiling of basal signaling patterns in nine healthy cell subsets. (A)  Summary of the basal phosphorylation state of 9 signaling pro-
teins associated with NF-κB, PI3K-AKT-mTOR (AKT, 4E-BP1, PLCG1 and p70-S6K), JAK-STAT (STAT1 and STAT3), MAPK (ERK and CREB) in three healthy individuals.
Matched peripheral blood (PB) and bone marrow (BM) from the same healthy donors were profiled. Phosphorylation profiles for the indexed phosphoproteins were inves-
tigated in corresponding cell subsets in leukemic samples: acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL). (B)  Box plot representation
of population medians of p4EBP1, pPLCg1 and pSTAT in healthy PB and BM (left) and leukemic samples (right). Center lines of boxes show medians; box limits indicate
the 25th and 75th percentiles as determined by R software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented
by dots; data points are plotted as open circles. *Significant difference (two-way ANOVA, Tukey’s HSD) between all corresponding populations, unless specified as not
significant (ns). #Significance between AML and the corresponding healthy populations in both PB and BM. There were no significant differences between PB and BM in
any population for each of the measured phosphoproteins, *P<0.05, **P<0.005, ***P<0.0005. Healthy PB and BM (n=3), AML (n=6), B-ALL (n=2).  (Continued on the
next page)
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Discussion 
Applying a high throughput, multi-parametric single-
cell assay, we aimed to assess the diversity in drug effects
on multiple cell populations in individual donor samples.
Therapeutic efficacy was determined ex vivo using com-
plex mixtures of cells to more realistically recapitulate the
native environment. Our results demonstrate that cell sub-
types are drastically different from each other with respect
to macromolecule abundance, signaling profiles and drug-
response patterns against a diverse collection of anticancer
drugs. As such, this study provides a comprehensive por-
trait of the drug sensitivity landscape in hematologic cell
subsets and reveals drug responses that are tied to specific
cell lineages. Importantly, cell subset-specific sensitivity
and resistance mechanisms were clearly reflected in their
malignant counterpart. 
Variation in drug responses can arise in healthy hemato-
logic cell subsets due to differences in signaling state and
transcriptional programs attributed to their cellular func-
tion or phenotype. Many of the signaling events are tight-
ly regulated in cellular subsets2 and may often determine
their innate sensitivity to drug treatment. For example, the
basal state of pSTAT3 could explain the diversity of the ex
vivo responses to BCL2 inhibitors observed between
healthy cell subsets. In relation to this, we have previously
reported a critical role of the JAK-STAT pathway in vene-
toclax resistance in AML, which could be reversed using a
combination of the JAK1/2 inhibitor ruxolitinib, and vene-
toclax.32 Although changes in signaling behaviors are com-
monly detected in malignant cells,7 understanding basal
signaling in the cell-of-origin is fundamental to identify
cancer vulnerabilities or off target effects that are lineage
specific.  
Profiling healthy and malignant cells (from multiple
hematologic malignancies) revealed that the cell-of-ori-
gin associated signaling events and drug responses were
also retained in the disease context of the affected cell
type.  Hence, the profiling presented here provides new
targeting opportunities in previously unexplored disease
indications. Venetoclax sensitivity in B cells may reflect
its efficacy in CLL and other B-cell malignancies,33 which
could also be exploited in diseases where B-cell depletion
is considered, i.e. in rheumatoid arthritis. Similar to other
studies,34,35 we demonstrated midostaurin efficacy in CLL
and ALL, which may be ascribed to the intrinsic response
detected in CD19+ cells. Efficacy was also detected in
CD34+CD38+ cells from AML (n=1) with WT FLT3. This
observation may reflect its efficacy reported in AML
with WT FLT3.24 Although NK-cell malignancies are
rare, they are often highly aggressive and refractory in
nature.36 We found that dexamethasone and midostaurin
targeted NK cells with similar efficacy as B cells, impli-
cating a potential clinical utility of these drugs for NK-
cell malignancies. 
Expression of antioxidant enzymes and calprotectin
(S100A8/S100A9) is associated with drug resistance,
including resistance to dexamethasone, which has been
documented in both hematologic and solid tumors.29,37-40
We noted that healthy monocytes displaying elevated
expression of these proteins are intrinsically resistant to
dexamethasone. Dexamethasone induced apoptosis of
lymphocytes is attributed to free radical generation, an
effect that can be counteracted by antioxidant enzymes
such as catalase, which may itself confer in monocytes
resistance to steroids.30,41 Furthermore, the monocyte
expansion observed with dexamethasone treatment could
be explained by its ability to mimic IL1B activation of
IL1R,42 which stimulates their proliferation. This phenom-
enon had previously been observed in murine
M.M. Majumder et al.
1536 haematologica | 2020; 105(6)
Figure 6. (continued from the previous page) (C)  Stacked histogram representations of pERK, p4E-BP1, pSTAT3 and pPLCg1 phosphorylation status across cell types
in an AML patient and healthy donor samples (paired BM and PB). Immunophenotype of the presented samples are provided in Online Supplementary Figure S1B.
(D) Phosphorylation of STAT3 in five healthy cell types from three healthy individuals presented as mean±standard error of mean (SEM) arcsinh values derived from
mass cytometry analysis. (E) Venetoclax response in cell types displayed as SEM of drug sensitivity score (DSS) values for three healthy donors. A higher response
to venetoclax correlated with reduced phosphorylation of STAT3. PDC: plasmacytoid dendritic cells; NK: natural killer. 
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Figure 7. Systematic comparison of drug responses in healthy cell-of-origin and corresponding cell types from hematologic malignancies. (A-F) Ex vivo drug respons-
es presented as drug sensitivity scores (DSS) of healthy cell types (CD3, n=4; CD14, n=4; CD19, n=2; CD34, n=2; and CD138, n=3) were compared to malignant
counterparts in a cohort of 281 primary samples for bortezomib, clofarabine, dexamethasone, omipalisib, venetoclax and navitoclax. Samples included both pub-
lished and unpublished datasets generated at our facility for chronic myeloid leukemia (CML) (n=13),10,11 chronic myelomonocytic leukemia (CMML) (n=11),12
myelodysplastic syndromes (MDS) (n=4), acute myeloid leukemia (AML) (n=145),9,12 B-cell acute lymphoblastic leukemia (B-ALL) (n=14),13 chronic lymphocytic
leukemia (CLL) (n=4),12 T-cell prolymphocytic leukemia (T-PLL) (n=40),14 multiple myeloma (MM) (n=50)15 and other hematologic malignancies (n=6). AML and MM
samples were subdivided depending on whether they were derived from newly diagnosed (D) and relapsed (R) samples. T-PLL and MM samples were tested with
enriched CD8+ and CD138+ cells. Results provide evidence that response in healthy cell subsets is predictive of responses observed in the malignant cell counter-
parts. A comparison between drug effects on CD14+ and CD34+ cells derived from healthy individuals and AML samples are displayed in Online Supplementary Figure
S13 and S14. B-PLL: B-cell prolymphocytic leukemia.
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monocytes,43 as well in acute monocytic leukemia [AML,
French-American-British (FAB) subtype M5] where gluco-
corticoid treatment may further lead to an increase in blast
population, fueling disease progression.44 Therefore,
understanding the cytoprotective mechanisms operating
in healthy cell subsets could also provide crucial insights
into drug resistance mechanisms in patients.
Cancer immunotherapies and drugs modulating the
immune system are emerging as important treatment
modalities for hematologic and solid tumors.45,46 Preserving
cytotoxic lymphocytes is critical for their efficacy and
may have significant consequences on long-lasting anti-
tumor adaptive immunity, likely responsible for durable
clinical responses. In our study, few inhibitors showed a
selective effect on a single cell type; instead, effects were
either directed to multiple cell types or in a non-selective
manner to all exposed cells. For example, dexamethasone
and midostaurin depleted CD19+ B cells and CD56+ NK
cells. Similarly, venetoclax depleted CD3+CD4- cytotoxic
T cells, among other cell types. Reduction of immune
effector cells (mainly cytotoxic T cells and NK cells) are
particularly relevant because of their key role in cancer
immunosurveillance and immunotherapy.47 Therefore,
profiling the unintended effects of small molecules on
effector cells, which are used in combination with
immunotherapies, is fundamental to the selection of
rational combination partners, and to preserve the quality
and quantity of immune cells in patients.
In summary, the findings presented in this study suggest
that dissecting drug responses in hematologic cell lineages
could represent an invaluable tool to reveal the full spec-
trum of cellular effects, identify novel drug resistance
mechanisms, and to predict off target effects of small mol-
ecules. We envision that incorporating the assessment of
cell lineage-specific drug responses into routine proce-
dures in preclinical drug development holds great promise
in identifying new therapeutic niches of small molecules
and improve precision in therapies, particularly for hema-
tologic malignancies.
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